Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
Liu. Rongjie R; Chen. Yituo Y; Huang. Haosheng H; Li. Xiang X; Lv. Junlei J; Jiang. Liting L; Jiang. Hongyi H; Wu. Chenyu C; Chen. Weikai W; Xu. Hongwei H; Zhu. Zhefan Z; Cai. Haoxu H; Xiao. Jian J; Yin. Lihui L; Ni. Wenfei W
Key Findings
- Semax improves functional recovery after spinal cord injury in female mice.
- The peptide reduces lysosomal membrane damage and related cell death by lowering oxidative stress.
- Semax acts on the mu‑opioid receptor, which regulates USP18 and the deubiquitination of the FTO protein.
Practical Outcomes
- For most biohackers, this research does not yet translate into a usable protocol, as it is limited to animal models of spinal injury. There is no dosage, safety, or efficacy data for humans, and the findings are specific to nerve repair rather than general longevity or performance enhancement.
Summary
In female mice with a spinal cord injury, the synthetic peptide Semax helped the animals recover better. It seems to work by binding to the mu‑opioid receptor, which then influences a protein called USP18 and reduces harmful changes to other proteins involved in cell stress. The study was done in mice and cell cultures, not in people.
Abstract
Lysosomal membrane permeabilization (LMP) is exacerbated following spinal cord injury (SCI), leading to increased neuronal cell death. Ubiquitination may affect LMP by regulating the stability and functionality of lysosomal membranes. Semax, a synthetic heptapeptide, comprising the ACTH (4-7) fragment and a C-terminal Pro-Gly-Pro tripeptide, exhibits neuroprotective properties and improves cognitive function. Given the key roles of LMP and ubiquitination in SCI pathophysiology, this study investigated how Semax could modulate these pathways to affect functional recovery following SCI. An SCI mouse model was generated by impacting the spinal cord of female C57BL/6 mice at T9-T10. Functional recovery in SCI mice was evaluated using histochemical methods, along with footprint analysis, Basso scores and inclined plane tests. Marker levels and distributions in the SCI model and in the PC12 cell neuroinflammation model were analysed using immunofluorescence, Western blot, RT-qPCR and transmission electron microscopy. RNA sequencing, network pharmacology and molecular docking were used to identify possible molecular targets of Semax. Semax improved SCI functional recovery and inhibited LMP-related pyroptosis in SCI mice and neuroinflammation models, by decreasing oxidative stress. RNA-seq and other analyses found that Semax regulated the ubiquitin specific protease USP18. USP18 knockdown confirmed Semax's role in SCI recovery. Network pharmacology and docking revealed the μ-opioid receptor as a Semax target. Semax promoted SCI functional recovery by targeting μ-opioid receptors, which regulated USP18 and, subsequently, deubiquitination of the fat mass and obesity-associated protein (FTO), suggesting its potential for SCI treatment.
Study Information
pubmed
2025
2025-07-21T00:00:00.000Z
10.1111/bph.70122
86